| scholarly article | Q13442814 |
| P356 | DOI | 10.1126/SCIENCE.8278812 |
| P698 | PubMed publication ID | 8278812 |
| P2093 | author name string | C J Eyermann | |
| C N Hodge | |||
| J L Meek | |||
| L T Bacheler | |||
| M J Otto | |||
| M M Rayner | |||
| P K Jadhav | |||
| P Y Lam | |||
| Y N Wong | |||
| Y Ru | |||
| P2860 | cites work | The Protein Data Bank: a computer-based archival file for macromolecular structures | Q27860989 |
| The development of versions 3 and 4 of the Cambridge Structural Database System | Q28090570 | ||
| P433 | issue | 5145 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | HIV | Q15787 |
| P304 | page(s) | 380-4 | |
| P577 | publication date | 1994-01-21 | |
| P1433 | published in | Science | Q192864 |
| P1476 | title | Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors | |
| P478 | volume | 263 |
| Q42427561 | (2E)-2-[1-(2-Hydroxy-4-methoxyphenyl)ethylidene]-N-phenylhydrazinecarboxamide monohydrate |
| Q85373114 | 1,4-Diamination of Cyclic Dienes via a (4 + 3) Cycloaddition of Diaza-allyl Cationic Intermediates |
| Q44830561 | 1H-1,3-diazepines, 5H-1,3-diazepines, 1,3-diazepinones, and 2,4-diazabicyclo[3.2.0]heptenes. |
| Q92735475 | 2,5-Anhydro sugar diacid and 2,5-anhydro sugar diamine based C 2 symmetric peptidomimetics as potential HIV-1 protease inhibitors |
| Q38553723 | 3DFS: A New 3D Flexible Searching System for Use in Drug Design |
| Q34483315 | 7 Isothermal Titration Calorimetry in Drug Discovery |
| Q42557837 | A Force Field with Discrete Displaceable Waters and Desolvation Entropy for Hydrated Ligand Docking |
| Q74781299 | A Novel Class of Herbicides (Specific Inhibitors of Imidazoleglycerol Phosphate Dehydratase) |
| Q52265017 | A comparison of heuristic search algorithms for molecular docking. |
| Q38558151 | A hybrid approach for addressing ring flexibility in 3D database searching |
| Q41504987 | A new class of models for computing receptor-ligand binding affinities |
| Q74101738 | A novel approach to the design of inhibitors of human secreted phospholipase A2 based on native peptide inhibition |
| Q36279404 | A preference-based free-energy parameterization of enzyme-inhibitor binding. Applications to HIV-1-protease inhibitor design |
| Q74613343 | A quantitative structure-activity relationship study on some HIV-1 protease inhibitors using molecular connectivity index |
| Q34937524 | A review of protein-small molecule docking methods |
| Q72816258 | A shape- and chemistry-based docking method and its use in the design of HIV-1 protease inhibitors |
| Q83185258 | Accounting for Solvent in Structure-Based Drug Design |
| Q38014544 | Accounting for water molecules in drug design |
| Q51552985 | AcquaAlta: A Directional Approach to the Solvation of Ligand–Protein Complexes |
| Q61833165 | Active-site-directed 3D database searching: Pharmacophore extraction and validation of hits |
| Q42279527 | Alpha-ketoamide Phe-Pro isostere as a new core structure for the inhibition of HIV protease |
| Q60951246 | An Improved Receptor-Based Pharmacophore Generation Algorithm Guided by Atomic Chemical Characteristics and Hybridization Types |
| Q42069286 | Analysis of factors influencing hydration site prediction based on molecular dynamics simulations |
| Q28379312 | Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo |
| Q31979080 | Anatomy by computer experiment of the exchange of a water molecule buried in human apolipoprotein E. |
| Q71855433 | Anisotropic rotational diffusion of perdeuterated HIV protease from 15N NMR relaxation measurements at two magnetic fields |
| Q27670428 | Anopheles gambiae odorant binding protein crystal complex with the synthetic repellent DEET: implications for structure-based design of novel mosquito repellents |
| Q39683244 | Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production |
| Q28368090 | Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease |
| Q28378879 | Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease |
| Q35366050 | Antiviral therapy for human immunodeficiency virus infections |
| Q37356313 | Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2 |
| Q27702054 | Application of the PM6 semi-empirical method to modeling proteins enhances docking accuracy of AutoDock |
| Q47342876 | AquaMMapS: an alternative tool to monitor the role of water molecules during protein-ligand association. |
| Q30922198 | Aryl ureas represent a new class of anti-trypanosomal agents |
| Q27664164 | Autocatalytic maturation, physical/chemical properties, and crystal structure of group N HIV-1 protease: Relevance to drug resistance |
| Q32079439 | Automated Docking and the Search for HIV Protease Inhibitors |
| Q46836531 | BUILDER v.2: improving the chemistry of a de novo design strategy |
| Q36941964 | Back‐Scattering Interferometry: An Ultrasensitive Method for the Unperturbed Detection of Acetylcholinesterase–Inhibitor Interactions |
| Q30392142 | Beyond Membrane Protein Structure: Drug Discovery, Dynamics and Difficulties |
| Q24530002 | Bile pigments as HIV-1 protease inhibitors and their effects on HIV-1 viral maturation and infectivity in vitro |
| Q73045237 | C2-symmetrical tetrahydroxyazepanes as inhibitors of glycosidases and HIV/FIV proteases |
| Q57647392 | Can cyclic HIV protease inhibitors bind in a non-preferred form? An ab initio, DFT and MM-PB(GB)SA study |
| Q41107892 | Capture-Collapse Heterocyclization: 1,3-Diazepanes by C-N Reductive Elimination from Rhodacyclopentanones |
| Q41518687 | Characterising non-covalent interactions with the Cambridge Structural Database |
| Q28368832 | Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor |
| Q30418854 | Chemical ecology: a view from the pharmaceutical industry |
| Q45743802 | Cloning of the bovine leukemia virus proteinase in Escherichia coli and comparison of its specificity to that of human T-cell leukemia virus proteinase |
| Q36280688 | Cluster analysis of consensus water sites in thrombin and trypsin shows conservation between serine proteases and contributions to ligand specificity |
| Q51983899 | Comparing ligand interactions with multiple receptors via serial docking. |
| Q44904068 | Comparing the quality and predictiveness between 3D QSAR models obtained from manual and automated alignment |
| Q52418847 | Computational combinatorial ligand design: application to human alpha-thrombin |
| Q41585193 | Computational tools for structure-based ligand design |
| Q34945073 | Conformation of inhibitor-free HIV-1 protease derived from NMR spectroscopy in a weakly oriented solution |
| Q72145466 | Conformationally constrained o-tolylpiperazine camphorsulfonamide oxytocin antagonists. Structural modifications that provide high receptor affinity and suggest a bioactive conformation |
| Q42670601 | Consensus scoring for ligand/protein interactions |
| Q27646453 | Crystal Structure of Lysine Sulfonamide Inhibitor Reveals the Displacement of the Conserved Flap Water Molecule in Human Immunodeficiency Virus Type 1 Protease |
| Q62673043 | Crystal structure of a novel synthetic inhibitor of HIV-1 protease |
| Q27730225 | Crystal structures of HIV-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptide isostere |
| Q35259915 | Current and Novel Inhibitors of HIV Protease |
| Q41080777 | Current computational tools for de novo ligand design |
| Q40565305 | Current methods for site-directed structure generation. |
| Q43523710 | Cyclophilin A Inhibition: Targeting Transition-State-Bound Enzyme Conformations for Structure-Based Drug Design |
| Q28369100 | DMP 323, a nonpeptide cyclic urea inhibitor of human immunodeficiency virus (HIV) protease, specifically and persistently blocks intracellular processing of HIV gag polyprotein |
| Q30770159 | DREAM++: flexible docking program for virtual combinatorial libraries |
| Q77370373 | De Novo Design and Discovery of Cyclic HIV Protease Inhibitors Capable of Displacing the Active-Site Structural Water Molecule |
| Q42538239 | Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors |
| Q44387101 | Design and synthesis of broad-based mono- and bi- cyclic inhibitors of FIV and HIV proteases |
| Q72145444 | Design of orally bioavailable, symmetry-based inhibitors of HIV protease |
| Q34236642 | Discovery and clinical development of HIV-1 protease inhibitors |
| Q34906937 | Discovery of nonpeptide, peptidomimetic peptidase inhibitors that target alternate enzyme active site conformations |
| Q36091270 | Disease-Specific Differentiation Between Drugs and Non-Drugs Using Principal Component Analysis of Their Molecular Descriptor Space. |
| Q57976081 | Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4 |
| Q43555843 | Does a diol cyclic urea inhibitor of HIV-1 protease bind tighter than its corresponding alcohol form? A study by free energy perturbation and continuum electrostatics calculations |
| Q45753956 | Early experience with protease inhibitors in human immunodeficiency virus-infected children |
| Q34462935 | Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. |
| Q42680896 | Effects of protonation state of Asp181 and position of active site water molecules on the conformation of PTP1B |
| Q53678858 | Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes |
| Q37439036 | Energetics of displacing water molecules from protein binding sites: consequences for ligand optimization |
| Q27636521 | Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets |
| Q44190842 | Enhanced docking with the mining minima optimizer: acceleration and side-chain flexibility |
| Q42549394 | Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition |
| Q38737287 | Estimation of kinetic and thermodynamic ligand-binding parameters using computational strategies |
| Q34450059 | Evidence for the role of cyclic AMP-responsive elements in human virus replication and disease |
| Q36999137 | Evolution under Drug Pressure Remodels the Folding Free-Energy Landscape of Mature HIV-1 Protease |
| Q27641946 | Exploration of the P6/P7 region of the peptide-binding site of the human class II major histocompatability complex protein HLA-DR1 |
| Q44801403 | Flexibility and function in HIV-1 protease |
| Q52052521 | Fragment-Based Flexible Ligand Docking by Evolutionary Optimization |
| Q30156028 | Free Energy Calculations of Mutations Involving a Tightly Bound Water Molecule and Ligand Substitutions in a Ligand-Protein Complex. |
| Q51917215 | From modeling to medicinal chemistry: automatic generation of two-dimensional complex diagrams |
| Q58080237 | Gaussian accelerated molecular dynamics for elucidation of drug pathways |
| Q35112794 | Genetic variability: The key problem in the prevention and therapy of RNA‐based virus infections |
| Q36691099 | HIV protease inhibitor HOE/BAY 793, structure-activity relationships in a series of C2-symmetric diols |
| Q33834118 | HIV protease: enzyme function and drug resistance |
| Q36914395 | HIV-1 protease flaps spontaneously close to the correct structure in simulations following manual placement of an inhibitor into the open state |
| Q31029932 | HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations |
| Q43609000 | HIV-1 protease inhibitors containing an N-hydroxyamino acid core structure. |
| Q34050688 | HIV-1 protease: maturation, enzyme specificity, and drug resistance. |
| Q43278152 | High-affinity inhibitors of tRNA-guanine transglycosylase replacing the function of a structural water cluster |
| Q59125582 | Highly efficient isocyanate-free microwave-assisted synthesis of [6]-oligourea |
| Q28379226 | Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogs |
| Q33229875 | Hydration changes in the association of Hoechst 33258 with DNA. |
| Q42854419 | Hydration of protein-RNA recognition sites |
| Q40985936 | Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore |
| Q33804495 | Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain |
| Q28485115 | Identification of novel HIV 1--protease inhibitors: application of ligand and structure based pharmacophore mapping and virtual screening |
| Q51993079 | Identification of symmetries in molecules and complexes |
| Q40993237 | Identifying small-molecule lead compounds: the screening approach to drug discovery |
| Q90844765 | Imidazolidinones and Imidazolidine-2,4-diones as Antiviral Agents |
| Q27677497 | Impact of Ligand and Protein Desolvation on Ligand Binding to the S1 Pocket of Thrombin |
| Q27733420 | Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450 |
| Q24794072 | Improved prediction of HIV-1 protease-inhibitor binding energies by molecular dynamics simulations |
| Q36077609 | Improving the description of salt bridge strength and geometry in a Generalized Born model |
| Q29620622 | In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors |
| Q35045753 | Inclusion of multiple fragment types in the site identification by ligand competitive saturation (SILCS) approach |
| Q30359220 | Incorporating replacement free energy of binding-site waters in molecular docking. |
| Q47276113 | Inhibition and substrate recognition--a computational approach applied to HIV protease |
| Q30663203 | Inhibition of human endogenous retrovirus-K10 protease in cell-free and cell-based assays |
| Q46084740 | Insights into the functional role of protonation states in the HIV-1 protease-BEA369 complex: molecular dynamics simulations and free energy calculations |
| Q63344408 | Integrative Theory/Experiment-Driven Exploration of a Multicomponent Reaction towards Imidazoline-2-(thi)ones |
| Q36672497 | Interaction of HIV-1 aspartic protease with its inhibitor, by molecular dynamics and ab initio fragment molecular orbital method |
| Q41158674 | Interaction of ganoderic acid on HIV related target: molecular docking studies |
| Q30010103 | Interfacial water molecules in SH3 interactions: Getting the full picture on polyproline recognition by protein-protein interaction domains |
| Q27678824 | Investigation of the binding pocket of human hematopoietic prostaglandin (PG) D2 synthase (hH-PGDS): A tale of two waters |
| Q27653045 | Involvement of Water in Carbohydrate−Protein Binding: Concanavalin A Revisited |
| Q55005046 | Iron-catalyzed urea synthesis: dehydrogenative coupling of methanol and amines |
| Q42905020 | Isoselenocyanates derived from amino acid esters: an expedient synthesis and application to the assembly of selenoureidopeptidomimetics, unsymmetrical Selenoureas and selenohydantoins |
| Q41318459 | Just add water! The effect of water on the specificity of protein-ligand binding sites and its potential application to drug design |
| Q38337597 | Kinetics, in silico docking, molecular dynamics, and MM‐GBSA binding studies on prototype indirubins, KT5720, and staurosporine as phosphorylase kinase ATP‐binding site inhibitors: The role of water molecules examined |
| Q64939757 | LAGUERRE-INTERSECTION METHOD FOR IMPLICIT SOLVATION. |
| Q47687247 | LIGSITE: automatic and efficient detection of potential small molecule-binding sites in proteins |
| Q59795950 | Ligand Binding Free Energies with Adaptive Water Networks: Two-Dimensional Grand Canonical Alchemical Perturbations |
| Q49374902 | Ligand Binding Pathways and Conformational Transitions of the HIV Protease |
| Q52066525 | Ligand-receptor docking with the Mining Minima optimizer |
| Q30981041 | Liquid-phase parallel synthesis of ureas |
| Q32014468 | Mass spectrometric and thermodynamic studies reveal the role of water molecules in complexes formed between SH2 domains and tyrosyl phosphopeptides |
| Q33879450 | Mechanism of the Association Pathways for a Pair of Fast and Slow Binding Ligands of HIV-1 Protease. |
| Q35987132 | Modeling Protein−Ligand Binding by Mining Minima |
| Q27757042 | Molecular Recognition of Cyclic Urea HIV-1 Protease Inhibitors |
| Q43195999 | Molecular docking and 3D-QSAR studies of HIV-1 protease inhibitors. |
| Q52250653 | Molecular mechanics calculations of proteins. Comparison of different energy minimization strategies |
| Q38272394 | Molecular mimicry of substrate oxygen atoms by water molecules in the beta-amylase active site. |
| Q73442683 | Molecular recognition at the thrombin active site: structure-based design and synthesis of potent and selective thrombin inhibitors and the X-ray crystal structures of two thrombin-inhibitor complexes |
| Q38335784 | Molecular recognition in chemical and biological systems |
| Q84050320 | Multiple receptor conformation docking and dock pose clustering as tool for CoMFA and CoMSIA analysis – a case study on HIV-1 protease inhibitors |
| Q44005248 | Novel inhibition of porcine pepsin by a substituted piperidine. Preference for one of the enzyme conformers |
| Q30400221 | On Lattice Protein Structure Prediction Revisited |
| Q72593914 | On the use of LUDI to search the Fine Chemicals Directory for ligands of proteins of known three-dimensional structure |
| Q36852276 | PRO_SELECT: combining structure-based drug design and combinatorial chemistry for rapid lead discovery. 1. Technology |
| Q43161207 | Pharmacophore modeling using site-identification by ligand competitive saturation (SILCS) with multiple probe molecules. |
| Q40651251 | Phase I/II Study of the Toxicity, Pharmacokinetics, and Activity of the HIV Protease Inhibitor SC-52151 |
| Q28369098 | Potency and selectivity of inhibition of human immunodeficiency virus protease by a small nonpeptide cyclic urea, DMP 323 |
| Q27647185 | Potent New Antiviral Compound Shows Similar Inhibition and Structural Interactions with Drug Resistant Mutants and Wild Type HIV-1 Protease † |
| Q41112862 | Predicting the structure of protein complexes: a step in the right direction |
| Q28285760 | Prediction of binding constants of protein ligands: a fast method for the prioritization of hits obtained from de novo design or 3D database search programs |
| Q47225368 | Prediction of ordered water molecules in protein binding sites from molecular dynamics simulations: The impact of ligand binding on hydration networks. |
| Q30495095 | Prediction of the water content in protein binding sites |
| Q30994627 | Pressure-induced structural transition of mature HIV-1 protease from a combined NMR/MD simulation approach |
| Q40405021 | Progress in anti-HIV structure-based drug design |
| Q44125156 | Progress toward virtual screening for drug side effects. |
| Q40206787 | Properties of water molecules in the active site gorge of acetylcholinesterase from computer simulation |
| Q39468942 | Protease Inhibitors as Antiviral Agents |
| Q27861108 | Protein backbone angle restraints from searching a database for chemical shift and sequence homology |
| Q28368080 | Protein structure-based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus protease |
| Q42739559 | Quantifying water-mediated protein-ligand interactions in a glutamate receptor: a DFT study |
| Q73346889 | Quantitative structure-activity relationship studies on cyclic cyanoguanidines acting as HIV-1 protease inhibitors |
| Q28481339 | Rapid and accurate prediction and scoring of water molecules in protein binding sites |
| Q40775925 | Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite |
| Q40516667 | Recombining the structures of HIV integrase, RuvC and RNase H. |
| Q74848565 | Regiocontrolled Cyclization Reaction of N-(2-Hydroxyethyl)ureas by Transfer of Activation: One-Pot Synthesis of 2-Imidazolidinones |
| Q47149307 | Replica-Exchange and Standard State Binding Free Energies with Grand Canonical Monte Carlo |
| Q42130025 | Reproducing Crystal Binding Modes of Ligand Functional Groups Using Site-Identification by Ligand Competitive Saturation (SILCS) Simulations |
| Q44103468 | Resistance profiles of cyclic and linear inhibitors of HIV-1 protease |
| Q38393674 | Retroviral proteases and their roles in virion maturation |
| Q28379544 | S-1153 Inhibits Replication of Known Drug-Resistant Strains of Human Immunodeficiency Virus Type 1 |
| Q28368263 | Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor |
| Q34050698 | Selection of HIV replication inhibitors: chemistry and biology |
| Q78427596 | Semicochliodinol A and B: Inhibitors of HIV-1 Protease and EGF-R Protein Tyrosine Kinase Related to Asterriquinones Produced by the Fungus Chrysosporium merdarium. |
| Q30333072 | Sensitivity of molecular docking to induced fit effects in influenza virus neuraminidase. |
| Q57080898 | Simple cis-epoxide-based inhibitors of HIV-1 protease |
| Q27682046 | Single amino acid exchange in bacteriophage HK620 tailspike protein results in thousand-fold increase of its oligosaccharide affinity |
| Q74824968 | Solid and Solution Phase Organic Syntheses of Oligomeric Thioureas |
| Q34657222 | Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir |
| Q41891194 | Solvation studies of DMP323 and A76928 bound to HIV protease: Analysis of water sites using grand canonical Monte Carlo simulations |
| Q48049114 | Solvent effects on ligand binding to a serine protease |
| Q27477452 | Specific Inhibition of Bovine Viral Diarrhea Virus Replicase |
| Q34621250 | Specific inhibition of herpes simplex virus DNA polymerase by helical peptides corresponding to the subunit interface |
| Q45751051 | Stabilization from autoproteolysis and kinetic characterization of the human T-cell leukemia virus type 1 proteinase |
| Q46305004 | Stoichiometric Reactions of CO2 and Indium-Silylamides and Catalytic Synthesis of Ureas |
| Q57394678 | Stoichiometric Reactions of CO2 and Indium-Silylamides and Catalytic Synthesis of Ureas |
| Q33894988 | Strength of hydrogen bond network takes crucial roles in the dissociation process of inhibitors from the HIV-1 protease binding pocket. |
| Q27671357 | Structural and Biochemical Basis for Development of Influenza Virus Inhibitors Targeting the PA Endonuclease |
| Q27748161 | Structural foundation for the design of receptor antagonists targeting Escherichia coli heat-labile enterotoxin |
| Q45745385 | Structure based prediction of binding affinity of human immunodeficiency virus-1 protease inhibitors |
| Q27729437 | Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors |
| Q27654045 | Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography |
| Q27732560 | Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine |
| Q27644394 | Structure-Based Design and Synthesis of N ω -Nitro- l -Arginine-Containing Peptidomimetics as Selective Inhibitors of Neuronal Nitric Oxide Synthase. Displacement of the Heme Structural Water |
| Q36867191 | Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D. |
| Q27729874 | Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2 |
| Q36536497 | Structure-based drug design and potent anti-cancer activity of tricyclic 5:7:5-fused diimidazo[4,5-d:4′,5′-f][1,3]diazepines |
| Q30419784 | Structure-based drug design: progress, results and challenges |
| Q35053155 | Structure-based virtual screening: an overview |
| Q36640463 | Switches of hydrogen bonds during ligand-protein association processes determine binding kinetics. |
| Q43559051 | Symmetry-based inhibitors of HIV-1 protease. Design, synthesis and preliminary structure-activity studies of acylated 2,3-diamino-1-hydroxypropanes and 2,4 diamino-1-hydroxybutanes |
| Q34171394 | Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design |
| Q47120733 | Synthesis and Structure-Activity Relationships of Substituted Urea Derivatives on Mouse Melanocortin Receptors |
| Q58104555 | Synthesis and activity of HIV protease inhibitors |
| Q56945150 | Synthesis ofC2Symmetric Potential Inhibitors of HIV-1 Protease From D-Mannitol |
| Q43679582 | Synthesis, kinetic studies and molecular modeling of novel tacrine dimers as cholinesterase inhibitors |
| Q40532115 | Targeting HIV-1 protease: a test of drug-design methodologies |
| Q33857482 | Targeting the HIV-protease in AIDS therapy: a current clinical perspective |
| Q40536032 | The 'peptoid' approach to the design of non-peptide, small molecule agonists and antagonists of neuropeptides |
| Q46027695 | The Role of Bound Water in the Stability of the Triple-Helical Conformation of (Pro-Pro-Gly)10 |
| Q77749461 | The de novo design and synthesis of cyclic urea inhibitors of factor Xa: initial SAR studies |
| Q48548852 | The effect of a tightly bound water molecule on scaffold diversity in the computer-aided de novo ligand design of CDK2 inhibitors. |
| Q45002480 | The effect of tightly bound water molecules on the structural interpretation of ligand-derived pharmacophore models. |
| Q73364551 | The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds |
| Q36867020 | The open structure of a multi-drug-resistant HIV-1 protease is stabilized by crystal packing contacts |
| Q34390928 | The role of structure-based ligand design and molecular modelling in drug discovery |
| Q42537258 | The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues |
| Q88567611 | Thermodynamic Insight into the Effects of Water Displacement and Rearrangement upon Ligand Modifications using Molecular Dynamics Simulations |
| Q30480872 | Thermodynamic linkage between the binding of protons and inhibitors to HIV-1 protease |
| Q42536287 | Tricyclic ureas: a new class of HIV-1 protease inhibitors |
| Q27640114 | True interaction mode of porcine pancreatic elastase with FR136706, a potent peptidyl inhibitor |
| Q42273561 | Understanding molecular mechanisms of traditional Chinese medicine for the treatment of influenza viruses infection by computational approaches |
| Q44194304 | Understanding traditional Chinese medicine anti-inflammatory herbal formulae by simulating their regulatory functions in the human arachidonic acid metabolic network |
| Q27325362 | Unique Flap Conformation in an HIV-1 Protease with High-Level Darunavir Resistance. |
| Q84463054 | Unsymmetrical tetrasubstituted ureas from tertiary carbamoylimidazole: activation by AlMe3 |
| Q32065321 | Use of 3D QSAR Methodology for Data Mining the National Cancer Institute Repository of Small Molecules: Application to HIV-1 Reverse Transcriptase Inhibition |
| Q52023426 | Utilising structural knowledge in drug design strategies: applications using Relibase |
| Q33247681 | Virtual ligand screening: strategies, perspectives and limitations |
| Q34101595 | Visualization of macromolecular structures. |
| Q36715297 | Water at biomolecular binding interfaces |
| Q42592716 | Water-mediated recognition of t1-adenosine anchors Argonaute2 to microRNA targets. |
| Q48556382 | WaterScore: a novel method for distinguishing between bound and displaceable water molecules in the crystal structure of the binding site of protein-ligand complexes |
| Q36290001 | Waterdock 2.0: Water placement prediction for Holo-structures with a pymol plugin |
| Q50626015 | What has virtual screening ever done for drug discovery? |
| Q42384335 | trans-4,5-Dihydroxy-1,3-bis(4-methoxyphenyl)imidazolidine-2-thione |
| Q42114572 | trans-4,5-Dihydroxy-1,3-diphenylimidazolidine-2-thione |
Search more.